News Conference News AHA 2025 CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI Michael O'Riordan November 11, 2025
News Conference News AHA 2023 Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH Caitlin E. Cox November 12, 2023
News Conference News AHA 2022 RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl Todd Neale November 10, 2022
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News AHA 2022 CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis Yael L. Maxwell November 05, 2022
News Conference News AHA 2022 Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link L.A. McKeown November 01, 2022
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021
News Conference News AHA 2021 Bentracimab Rapidly, Safely Reverses Ticagrelor in Early REVERSE-IT Data Yael L. Maxwell November 15, 2021
News Conference News AHA 2021 Tricuspid Repair During Mitral Surgery Slows Disease Progression at 2 Years Caitlin E. Cox November 13, 2021
News Conference News AHA 2019 EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl Todd Neale November 18, 2019
News Conference News AHA 2018 REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides Todd Neale November 10, 2018
News Conference News AHA 2018 AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City Shelley Wood November 05, 2018
News Conference News AHA 2015 Inappropriate PCIs Slashed by Half Since First AUC Released, But Key Questions Remain Shelley Wood November 08, 2015
News Conference News AHA 2012 EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES Jason Kahn November 04, 2012
News Conference News PRISM Individualized Informed Consent Improves PCI Choice, Experience November 14, 2011